Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location
Journal of Clinical Microbiology · 17.12.2025 · 63 (12)
DOI: 10.1128/jcm.00706-25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 17.12.2025. Verfasst von B Van Der Pol und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Chlamydia Infections, Gonorrhea, Molecular Diagnostic Techniques, Mycoplasma Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Molecular Systems.
Abstract (Originalsprache)
Sexually transmitted infections, e.g., Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG), present with similar signs/symptoms and are often treated empirically due to delays in receiving diagnostic test results. This study evaluated the clinical performance of the Cobas Liat CT/NG/MG nucleic acid amplification test (NAAT) in detecting these pathogens in a point-of-care (POC) setting. This non-interventional, multicenter study recruited symptomatic/asymptomatic participants from 13 geographically diverse POC sites across the USA. Prospective clinician- and self-collected specimens (urine/vaginal swabs) were used to determine the sensitivity and specificity of the Cobas Liat CT/NG/MG test relative to the composite reference standard (CRS), determined using a combination of results from three FDA-approved NAATs and one laboratory-developed test. Among 4,800 evaluable participants, 40.4% ( n = 1,941) were symptomatic, and 51.9% ( n = 2,489) were female at birth. The Cobas Liat CT/NG/MG test demonstrated good clinical performance across all specimen types regardless of symptom status, with specificity >97% for each analyte, and sensitivity ≥92%, except female urine (≥CT 87%, NG ≥ 83%, MG ≥ 77%). The test was considered easy to use, and no statistically significant difference in performance results was observed between trained/untrained users. The Cobas Liat CT/NG/MG test demonstrated good clinical performance, with high sensitivity and specificity for CT/NG/MG detection, regardless of symptom status. The assay provides a short turn-around time (approximately 20 min) with centralized testing laboratory accuracy at the POC for self- and clinician-collected samples. POC testing can facilitate rapid pathogen identification and accurate treatment, thereby mitigating the need for empiric treatment. IMPORTANCE Nucleic acid amplification tests are the preferred method for diagnosing CT and NG infections and are the only reliable tests for MG; however, delays in receiving results can lead to empiric treatment, potentially causing misdiagnosis and overtreatment of STIs. Point-of-care testing could mitigate these issues by enabling rapid pathogen identification and treatment, but no rapid POC tests are currently available for the detection of CT, NG, and MG despite the similarity of symptoms, and these three pathogens being responsible for the majority of symptomatic STIs in some settings. Our findings suggest that the Cobas Liat CT/NG/MG assay may help to reduce reliance on empiric treatment of symptoms and minimize resulting return visits for unresolved infections. Use of the Cobas Liat CT/NG/MG assay may also result in improved patient outcomes, help realize population benefits by reducing the duration of infection and potentially transmission, and reduce healthcare costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
- Roche Molecular Systems, Pleasanton, California, USA.
- Planned Parenthood North Central States, Saint Paul, Minnesota, USA.
- Segal Trials North Miami Office, North Miami, Florida, USA.
- Planned Parenthood Gulf Coast, Houston, Texas, USA.
- BioCollections Worldwide, Inc., Miami, Florida, USA.
ORCID-Profile: B Van Der Pol, R A Lillis
Förderung
- Roche Molecular Systems
Zitieren
APA
Van Der Pol, B., Arcenas, R., Boraas, C., Chavoustie, S., Crane, L. L., d'Empaire, N., Ermel, A. C., Harnett, G., Hinestrosa, F., House, S., Lillis, R. A., Miller, J., Mills, A., Poblete, R., Young, S. A., & Liat CT/NG/MG Clinical Trial Study Group (2025). Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00706-25
Vancouver
Van Der Pol B, Arcenas R, Boraas C, Chavoustie S, Crane LL, d'Empaire N, et al. Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.00706-25
BibTeX
@article{VanDerPol2025,
author = {Van Der Pol, B and Arcenas, R and Boraas, C and Chavoustie, S and Crane, L L and d'Empaire, N and Ermel, A C and Harnett, G and Hinestrosa, F and House, S and Lillis, R A and Miller, J and Mills, A and Poblete, R and Young, S A and Liat CT/NG/MG Clinical Trial Study Group, Liat CT/NG/MG Clinical Trial Study Group},
title = {Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location},
journal = {Journal of Clinical Microbiology},
year = {2025},
doi = {10.1128/jcm.00706-25}
}
EUVIMED